Sabina Ugovšek

Ms. Sabina Ugovšek

University of Ljubljana, Faculty of Medicine
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
SUSabina Ugovšek
Sabina Ugovšek
MSMiran Sebestjen
Miran Sebestjen
Increased lipoprotein(a) (Lp(a)) levels are an independent predictor of coronary artery disease (CAD), degenerative aortic stenosis (DAS), and heart failure independent of CAD and DAS. Lp(a) levels are genetically determinated in an autosomal dominant mode, with great intra- and inter-ethnic diversity. Most variations in Lp(a) levels arise from genetic variations of the gene that encodes the apolipoprotein(a) component of Lp(a), the LPA gene. LPA is located on the long arm of chromosome 6, within region 6q2.6–2.7. Lp(a) levels increase cardiovascular risk through several unrelated mechanisms. Lp(a) quantitatively carries all of the atherogenic risk of low-density lipoprotein cholesterol, although it is even more prone to oxidation and penetration through endothelia to promote the production of foam cells. The thrombogenic properties of Lp(a) result from the homology between apolipoprotein(a) and plasminogen, which compete for the same binding sites on endothelial cells to inhibit fibrinolysis and promote intravascular thrombosis. LPA has up to 70% homology with the human plasminogen gene. Oxidized phospholipids promote differentiation of pro-inflammatory macrophages that secrete pro-inflammatory cytokines (e. g., interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor-α). The aim of this review is to define which of these mechanisms of Lp(a) is predominant in different groups of patients.

20 March 2021 in Archives of Medical Science
Verified
Journal Article
Open access
SUSabina Ugovšek
Sabina Ugovšek
Janja ZupanJanja Zupan
Janja Zupan
ALAndreja Rehberger Likozar
Andreja Rehberger Likozar
MSMiran Sebestjen
Miran Sebestjen
Atherosclerosis is a chronic inflammatory disease that is associated with risk of cardiovascular events. The best-characterised and well-standardised clinical indicator of inflammation is C-reactive protein. Current evidence-based drug therapies for prevention and treatment of cardiovascular diseases are mainly focused on reduction of low-density lipoprotein cholesterol. However, these drugs do not provide sufficient protection against recurrent cardiovascular events. One of the possible mechanisms behind this recurrence might be the persistence of residual inflammation. For the most commonly used lipid-lowering drugs, the statins, their reduction of cardiovascular events goes beyond lowering of low-density lipoprotein cholesterol. Here, we review the effects of these lipid-lowering drugs on inflammation, in terms of statins, ezetimibe, fibrates, niacin, proprotein convertase subtilisin/kexin type 9 inhibitors, bempedoic acid, ethyl eicosapentaenoic acid and antisense oligonucleotides. We focus in particular on C-reactive protein, and discuss how the effects of the statins might be related to reduced rates of cardiovascular events.

15 October 2025 in Biochemia Medica
Verified
Journal Article
Open access
PDF file
SUSabina Ugovšek
Sabina Ugovšek
JJJernej Jeras
Jernej Jeras
MŠMiran Šebeštjen
Miran Šebeštjen
JZJanja Zupan
Janja Zupan
Atherosclerosis is an active interaction between lipoproteins and inflammatory cells. Monocytes and macrophages are the most important immune cells involved in the process of atherosclerosis. They interact with atherogenic lipoproteins, in particular low density lipoprotein (LDL) cholesterol and lipoprotein(a) (Lp(a)). The increased concentration of the LDL cholesterol and Lp(a) accelerates the polarization of monocytes and macrophages toward proinflammatory phenotype and the formation of the foam cells. These cells then release large quantities of inflammatory cytokines that stimulate the oxidation of atherogenic lipoproteins that are even more atherogenic and contribute to the formation of foam cells and the secretion of the pro-inflammatory cytokines, thus creating a vicious circle. Surface marker C-C chemokine receptor type 2, expressed on monocytes/macrophages, enables their adhesion and migration into the subendothelial layer. The rupture of the atherosclerotic plaque on one hand, and the ability of the oxidized LDL cholesterol and Lp(a) to trigger arterial thrombosis by different mechanisms on the other hand, result in acute cardiovascular event. Here, we summarize the role of the monocytes and macrophages in atherosclerosis and explore the influence of LDL cholesterol and Lp(a) on monocytes and macrophages during the entire process of atherosclerosis, from its initiation to progression.

Verified
Journal Article
Open access
PDF file
SUSabina Ugovšek
Sabina Ugovšek
ALAndreja Rehberger Likozar
Andreja Rehberger Likozar
TLTina Levstek
Tina Levstek
KPKatarina Trebušak Podkrajšek
Katarina Trebušak Podkrajšek
Janja ZupanJanja Zupan
Janja Zupan
MSMiran Sebestjen
Miran Sebestjen
Lipoprotein(a) (Lp(a)) is an independent risk factor for future coronary events. Variants rs10455872 and rs3798220 in the gene encoding Lp(a) are associated with an increased Lp(a) concentration and risk of coronary artery disease. We aimed to determine whether in high-risk coronary artery disease patients these two genetic variants and the kringle IV type 2 (KIV-2) repeats are associated with impairment of inflammatory and hemostatic parameters. Patients after myocardial infarction with elevated Lp(a) levels were included. Blood samples underwent biochemical and genetic analyses. In carriers of the AC haplotype, the concentrations of tumor necrosis factor (TNF)-α (4.46 vs. 3.91 ng/L, p = 0.046) and plasminogen activator inhibitor-1 (PAI-1) (p = 0.026) were significantly higher compared to non-carriers. The number of KIV-2 repeats was significantly associated with the concentration of high-sensitivity C-reactive protein (ρ = 0.251, p = 0.038) and overall fibrinolytic potential (r = −0.253, p = 0.038). In our patients, a direct association between the AC haplotype and both TNF-α and PAI-1 levels was observed. Our study shows that the number of KIV-2 repeats not only affects proatherosclerotic and proinflammatory effects of Lp(a) but is also associated with its antifibrinolytic properties.

7 December 2023 in European Journal of Pharmacology
Verified
Journal Article
Open access
ALAndreja Rehberger Likozar
Andreja Rehberger Likozar
SUSabina Ugovšek
Sabina Ugovšek
MSMiran Sebestjen
Miran Sebestjen
Despite progress in treatment, elevated levels of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) (Lp(a)), represent a significant part of the residual risk. Both are associated with inflammation and the coagulation fibrinolytic system. The purpose of our research was to evaluate the effect of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) on lipid parameters and indicators of inflammation, coagulation and fibrinolysis. We included 100 post myocardial infarction (MI) patients with insufficiently controlled LDL-C values despite the maximum dose of statin, and highly elevated Lp(a). Patients received alirocumab or evolocumab (150 mg sc or 140 mg sc every two weeks, respectively), or placebo for 6 months. In patients receiving PCSK9i, a significant decrease in total cholesterol (TC), LDL-C, triglycerides (TG) and Lp(a), and an increase in high density lipoprotein cholesterol (p < 0.001 for all) was found. Before treatment, the concentrations of TC, LDL-C and TG correlated with the concentrations of thrombin activatable fibrinolysis inhibitor (r = 0.41, p < 0.001; r = 0.353, p < 0.001; r = 0.311, p = 0.003, respectively), and plasminogen activator inhibitor-1 (r = 0.302, p = 0.007; r = 0.218, p = 0.049; r = 0.278; p = 0.013, respectively). The concentrations of TC and LDL-C correlated with overall fibrinolytic potential (r = -0.220, p = 0.034; r = -0.207, p = 0.047, respectively). The concentration of TG was related to the concentration of interleukin 6 (r = 0.290, p = 0.004) and interleukin 8 (r = 0.332, p = 0.001). No correlations between Lp(a) and inflammatory or hemostatic variables were found. No associations were found after treatment. Our results show that inflammatory cytokines and fibrinolytic parameters are related to LDL-C and not Lp(a) in post-MI patients before and with neither of them following PCSK9i treatment. The trial registration number: NCT04613167, Date of registration: November 3, 2020.

23 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SUSabina Ugovšek
Sabina Ugovšek
ALAndreja Rehberger Likozar
Andreja Rehberger Likozar
TLTina Levstek
Tina Levstek
KPKatarina Trebušak Podkrajšek
Katarina Trebušak Podkrajšek
JZJanja Zupan
Janja Zupan
MŠMiran Šebeštjen
Miran Šebeštjen
The proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism, inflammation and haemostasis. Pathogenic gain-of-function variants in the PCSK9 gene are causative of autosomal-dominant form of familial hypercholesterolemia, while several PCSK9 alleles have been associated with elevated levels of low-density lipoprotein cholesterol (LDL-C) and an increased risk of cardiovascular disease. Elevated lipoprotein(a) (Lp(a)) levels, regardless of LDL-C levels, as well as functional and morphological changes in the arterial vessel wall predict future cardiovascular events. In our study, we aimed to identify whether treatment with statins nullifies the effect of four gain-of-function gene variants in PCSK9 on lipoproteins and arterial wall properties in high-risk post-myocardial infarction patients with severely elevated Lp(a) levels. We included 68 patients after myocardial infarction with elevated Lp(a) levels on maximal statin therapy. Biochemical analysis of lipid parameters and total PCSK9 levels were performed. Arterial wall properties were measured by ultrasound. Genotyping was performed for four gain-of-function, i.e. rs11206510, rs2479409, rs2479408 and rs1711503, and one intergenic, rs11591147 PCSK9 single nucleotide polymorphisms. The results showed no association between studied PCSK9 gene variants and lipid parameters, PCSK9 levels and arterial wall properties in our patient cohort. Clinical, biochemical and arterial wall parameters did not differ between the group with lower compared to group with higher number of PCSK9 alleles. Our results suggest that in high-risk patients after myocardial infarction with increased Lp(a) levels treated with statins the studied PCSK9 gain-of-function gene variants are associated neither with lipoproteins nor with arterial wall properties.